19:20 , Apr 19, 2019 |  BioCentury  |  Politics, Policy & Law

Thin U.S. biosimilars market fuels proposals to regulate biologics prices

Frustration over the failure of biosimilars to slash the costs of decades-old biologics has prompted a group of policy analysts to suggest abandoning attempts to copy biologics. Because the sole purpose of biosimilars is to...
15:47 , Mar 28, 2019 |  BioCentury  |  Product Development

Contracting practices limiting U.S. biosimilars uptake

The U.S. biosimilars market lags Europe’s and won’t catch up until physicians understand and become comfortable with the concept of similarity, Sheila Frame, who heads up Sandoz’s North American biosimilars business, told BioCentury. To create...
22:28 , Feb 26, 2019 |  BC Extra  |  Politics & Policy

Pharma CEOs present united front - except on biosimilars

Seven pharma leaders expressed strong support for eliminating rebates to PBMs and insurance companies, shifting from volume- to value-based reimbursement, and reducing out-of-pocket costs for drugs in testimony Tuesday to the Senate Finance Committee. The...
00:05 , Dec 12, 2018 |  BC Extra  |  Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

Merck & Co. Inc. (NYSE:MRK) said President of Global Human Health Adam Schechter will step down at the end of the year. The company will restructure his former position into two new roles effective Jan....
21:26 , Dec 4, 2018 |  BC Extra  |  Politics & Policy

Biosimilar makers back Pfizer in call to end misleading brand marketing

A group of biosimilar manufacturers including Pfizer Inc. (NYSE:PFE) urged FDA to produce supplemental guidance clarifying how to comply with existing law when communicating about biosimilars. The Biosimilars Forum sent its plea in a letter...
22:31 , Sep 4, 2018 |  BC Extra  |  Politics & Policy

Biosimilars companies urge Gottlieb to influence administration

Speaking at an FDA public hearing, representatives of biosimilars manufacturers Tuesday called on FDA Commissioner Scott Gottlieb to lobby federal agencies and Congress to address commercial practices that are limiting uptake of biosimilars. They also...
18:10 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

Mabpharm Ltd. (Taizhou, China) proposed Aug. 22 to list on the Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by CICC. Mabpharm is the second biotechnology company this week to file to...
22:52 , Aug 22, 2018 |  BC Extra  |  Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

Mabpharm Ltd. (Taizhou, China) proposed Wednesday to list on the Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by CICC. Mabpharm is the second biotechnology company this week to file to list...
03:14 , Aug 8, 2018 |  BC Extra  |  Politics & Policy

CMS opens private-sector negotiation to Medicare Part B

CMS unveiled details of a policy under the Trump administration's drug pricing blueprint that will apply private-sector negotiation tools into some Medicare Part B plans and create competition between Part B and D drugs. Plans...
17:51 , Aug 3, 2018 |  BC Week In Review  |  Company News

Celltrion wins another biosimilar infliximab lawsuit

A federal judge ruled July 30 that biosimilar Inflectra infliximab-dyyb from Celltrion Inc. (KOSDAQ:068270) does not infringe a patent from Johnson & Johnson (NYSE:JNJ) covering autoimmune drug Remicade infliximab. The decision follows a previous Celltrion...